Aveeno has looked to the medical community for its latest partnership.
The Kenvue-owned skin care brand has entered a three-year collaboration with Mayo Clinic, which will focus on research, education and innovation, a statement from Aveeno said.
That focus will be on clinical and pre-clinical studies into Triple Oat, which is a proprietary complex that also spawned a facial serum of the same name. That complex includes three different forms of oat, per the brand’s website.
“We are constantly pushing for innovation, staying on the cutting edge of research and testing, especially within our skin health portfolio,” said Dr. Caroline Tillett, chief scientific officer at Kenvue, in a statement. “Aveeno was the first brand to formulate colloidal oatmeal, and we are thrilled at the opportunity to collaborate with Mayo Clinic’s multi-disciplinary physicians to enhance our understanding of skin health. We care fiercely for those who use and recommend our products, and our goal is to deliver even greater solutions for ultimate skin health and wellness for both patients and consumers.”
Aveeno owner Kenvue, which debuted on the New York Stock Exchange in 2023, is being acquired by Kimberly-Clark Corp. in a deal that is expected to close later in 2026. The deal values Kenvue, which also owns Neutrogena, OGX and Tylenol, at $48.7 billion.
